CheckMate 649: A randomized, multicenter, open-label, phase III study of nivolumab (NIVO) plus ipilimumab (IPI) or nivo plus chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer Meeting Abstract
| Authors: | Moehler, M. H.; Janjigian, Y. Y.; Adenis, A.; Aucoin, J. S.; Boku, N.; Chau, I.; Cleary, J. M.; Feeney, K.; Franke, F. A.; Mendez, G. A.; Schenker, M.; Li, M.; Hitre, E.; Couture, F.; Karamouzis, M.; Etienne, P. L.; Ajani, J. A. |
| Abstract Title: | CheckMate 649: A randomized, multicenter, open-label, phase III study of nivolumab (NIVO) plus ipilimumab (IPI) or nivo plus chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer |
| Meeting Title: | 2018 Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2018 Jan 18-20 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-02-01 |
| Language: | English |
| ACCESSION: | WOS:000436174100184 |
| DOI: | 10.1200/JCO.2018.36.4_suppl.TPS192 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS192 -- Source: Wos |
